|
|
||
|
Home | About | A-Z Clinics + Services | Health Info | Research | Patients | Visitors | Careers | Media | Donations + Charities |
Second Trimester Screening (14 weeks to 20 weeks)Maternal Serum Screening and how it worksThe biochemistry of a developing baby has considerable impact on that of its mother. Not surprisingly, when fetal development is abnormal, maternal biochemistry sometimes reflects this. The high maternal serum alphafetoprotein (AFP) concentration associated with an open fetal neural tube defect is probably the most familiar instance of this. In screening for fetal disorders the South Australian Maternal Serum Antenatal Screening (SAMSAS) Programme measures three analytes in a mother’s blood when she is between 14 and 20 weeks pregnant. These are alpha-fetoprotein (AFP), free beta subunit of chorionic gonadotropin (b-hCG), and unconjugated estriol (uE3). These three analytes are normally produced by, or in support of, a fetus and its placenta and have known values at each stage of pregnancy. A number of fetal abnormalities and pregnancy pathologies result in one or more of these analytes changing from their normal values. The normal pattern of results becomes disturbed. Examples of some of the abnormal patterns found are given later in this booklet. Maternal serum screening for fetal abnormalities thus comes down to comparing the biochemical results found in a given mother’s blood with these patterns. If the results match one of the patterns, then the biochemical results are taken to indicate that the fetus is at increased risk of having that particular abnormality. If the results for all analytes fall within normal limits, then it is concluded that the fetus is not at increased risk of having an abnormality. Increased risk’ and ‘not at increased risk’ resultsIf maternal serum screening results fell clearly outside normal values when fetal development was abnormal, then biochemical screening would be able to declare each pregnancy normal or abnormal with certainty. In practice this does not occur. Results found when fetal development is abnormal overlap with those found in normal pregnancy. Because of this overlap, maternal serum screening cannot give a certain answer to the question "is this pregnancy normal?". It can only declare the pregnancy more likely to be (increased risk) or less likely to be (not at increased risk) that of an affected fetus. The measure of the SAMSAS Programme’s uncertainty in declaring a pregnancy normal or abnormal is given by the risk odds quoted on its results reports. A report stating increased risk of Down syndrome (1:50) means that on average one out of every 50 such reports issued by the SAMSAS Programme will truly refer to an affected pregnancy. The other 49 pregnancies will be unaffected by fetal Down syndrome. Conversely, a report stating not at increased risk (1:2600), means one pregnancy out of every 2600 receiving such a report will be affected by fetal Down syndrome. These figures reflect the extent to which the screening results from affected pregnancies overlap with those from the normal population in this condition. In counselling, these risk odds are sometimes referred to as the ‘woman’s risk’. Note, however, the quoted figures are more properly regarded as a measure of the uncertainty in the assessment of the risk, and do not stem from anything the woman has or has not done. How the SAMSAS Programme worksThe aim of the SAMSAS Programme is to provide accurate forewarning of certain fetal abnormalities and pregnancy pathologies to obstetricians, general practitioners and midwives as they manage the pregnancies under their care. To this end the SAMSAS Programme maintains a close liaison with ultrasonographers, health centres, antenatal clinics and counselling support structures. Ordering maternal serum screening Maternal serum screening is best ordered from the SAMSAS Programme using one of the Programme’s request forms (call (08) 8161 7285 for a supply). These come in pads of 25 with each request form accompanied by a copy of "Information for Parents about Maternal Serum Screening". This information is provided to facilitate pre-test counselling about the procedure. It is for parents to take away with them. (In the absence of a SAMSAS request form a standard pathology request form can be used. The instruction "send to WCH" should be clearly written upon the request form to ensure the request is forwarded to the SAMSAS Programme.) Testing Testing is performed every working day. Mothers can have their blood specimen taken at any one of the blood collection centres around the State. They do not have to come to the Women’s and Children’s Hospital for blood collection. Specimen required is 5-10mL clotted blood. Increased risk results When a pregnancy is found to be at increased risk of any of the screened conditions, further information is sent with the results report. Experience has shown that giving families these information sheets at the time they receive their report eases the way in which they deal with the information. If the pregnancy is screened at increased risk of Down syndrome the information sheet "Increased risk of Down syndrome - what does it mean?" is provided. Further interpretation of results is available by telephone (08) 8161 7285. Reports and follow-up Specimens are processed within one working day of receipt. Results are generally available by 4.00 pm by telephone. All reports indicating increased risk of a screened condition are faxed to the referring doctor or clinic, with a written report following by post or courier. Types of results encounteredOn the following pages are some of the patterns in test results recognised by the SAMSAS Programme. The range of values found for the four analytes, alpha-fetoprotein (AFP), free alpha subunit (a-hCG) and free beta subunit (b-hCG) of chorionic gonadotropin, and unconjugated estriol (uE3), are shown in box plot form. Please note that following the introduction of first trimester screening in 2001, a-hCG is no longer used to assess risk in second timester. Also note that most pregnancies are now screened in the first trimester and gestational age dated is calculated using the CRL (crown to rump length) measured by ultrasound using CRL upto 84 mm after which average ultrasound biometry is uesd. Because the serum concentration of each of these analytes changes as pregnancy progresses, values are expressed as Multiples of the population Median (MoM values) expected at the gestational age of the specimen being analysed. This allows the different values measured at different gestational ages to be compared directly with one another and interpreted consistently. For example, an AFP value of 41 KIU/L in the blood of a mother of 15 weeks gestation (where the median value for the population is 27 KIU/L) would be interpreted similarly to a maternal serum AFP value of 80 KIU/L in another mother who was of 20 weeks gestation (where the median value for the population is 53 KIU/L). Both results are 1.5 Multiples of the Median value expected for their gestational age, or 1.5 MoM. Note that the normal value for any analyte at any gestational age within the screening window of 15-20 weeks is 1.0 MoM.
All analyte values vary about 1 MoM (Multiples of the population Median value for the gestational age of the pregnancy). This is the pattern of analytes with which the results from each pregnancy are compared in screening for fetal abnormalities and pregnancy pathologies.
The Importance of Correct Gestational Age Assessment
Gestational age assessments made from ultrasonographic measurements are the most reliable. Almost 80% of all corrections of gestational age called through to the SAMSAS Programme come from reports issued on pregnancies where the initial estimation is by dates or other unspecified method. Any revision of the estimate of gestation requires a telephone call to the SAMSAS Programme ((08) 8161 7285) so that risks can be recalculated. This is important whether or not the original report indicated increased risk of any condition. Recalculation of risks is performed over the telephone. An amended report follows. Correct assessments of gestational age mean more accurate assessments of risk from the SAMSAS Programme, fewer falsely increased risk reports for doctors and clinics to deal with, and less unnecessary anxiety for families. Interpretation of Gestational Age Information by the SAMSAS ProgrammeGestational age information is presented to us in a number of ways. It is important that you give us your estimate of gestational age (in weeks and days) and the date upon which you made that estimate. The SAMSAS computer system will do the extrapolation to sample date. Transcription and calculation errors are then minimised. For risk assessment we have adopted the following conventions when interpreting gestational age information on request forms:
The Use of Ultrasound Dating and 'increased risk’ ResultsThe reason why ultrasound dating of pregnancy is given first place in the hierarchy of estimates shown on the previous page is given in the following table. It is found that the obstetric centres in South Australia which most frequently use ultrasound to date pregnancies before requesting maternal serum screening also have the fewest corrections of gestational age information following the issuing of ‘increased risk’ reports. Accurate initial dating produces fewer false positive results without reducing the detection of truly affected pregnancies (1996 SAMSAS Programme performance data).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Year | Pregnancies Screened |
Recalled 'increased risk' trisomy 21 |
Trisomy 21 detected |
| 1994 | 11535 | 466 (4.0%) | 11/15 (73.3%) |
| 1995 | 11381 | 646 (5.7%) | 11/17 (64.7%) |
| 1996 | 12125 | 845 (7.0%) | 12/15 (80%) |
| 1997 | 11410 | 773 (6.8%) | 22/27 (81.5%) |
| For Neural Tube Defects Pregnancies screened for NTD (1991-1997) Recalled 'increased risk' of NTD NTDs Detected |
85 565 2567 (3.0%) 89/103 (86.4%) |
Recommending amniocentesis to mothers aged 35 years or more at delivery would currently see this service offered to 13.5% of the pregnant population of South Australia (SA Pregnancy Outcome Report 1996). Characteristically about 51% of these would act upon the offer. In addition about 3% of mothers less than 35 at delivery would also request amniocentesis.
With an ‘increased risk’ result from maternal serum screening, the uptake of amniocentesis in these two groups in the past three years has been as follows:
| Pregnancies Screened |
Declared 'increased risk' |
Proceeded to amniocentesis |
|
| 1995 <35 years |
10553 828 |
453 (4.3%) 193 (23.3%) |
342 (75.5%) 128 (66.3%) |
| 1996 <35 years |
11188 937 |
594 (5.3%) 251 (26.8%) |
489 (82.3%) 173 (68.9%) |
| 1997 <35 years |
10445 965 |
563 (5.4%) 210 (21.8%) |
483 (85.8%) 175 (83.3%) |
For further information see Newsletter Updates 7 and 8
| ^TOP | FEEDBACK |
SITE INDEX |
DISCLAIMER |
CONTACT |
COPYRIGHT |
PRIVACY Last Modified: 04-12-2009 10:54:48 |